



## Lumendo closes 2.54 MCHF Seed financing round

**Renens, January 7th, 2022.** Lumendo announced today the closing of a 2.54 MCHF financing round to bring its novel endodontic treatment platform into clinical use.

The financing round was led by Dominik Lysek, PhD, partner at US-based Revere Partners. Co-investors were Zürich Cantonal Bank and Business Angels Switzerland.

Lumendo CEO, Andreas Schmocker, PhD, commented: “This Seed financing round is a major milestone for Lumendo. It allows us to translate our prototypes into a clinical workflow, ultimately moving closer towards the goal of disrupting the endodontic device and consumable market. The clinical proof of concept and validation with a prototype produced under ISO 13485 is the most important milestone on the path of getting market approval for our products, and make Lumendo a success”.

Dominik Lysek, partner at Revere Partners confirmed, that: “being one of the world’s top innovators in the financing of oral health startups, we strongly believe in the potential of Lumendo’s offering of a minimally invasive endodontic treatment solution. We are convinced that by providing faster and more ergonomic procedures we will improve treatment efficacy and success and thus enable a more reliable patient outcome. The ingenuity of Lumendo’s technology will allow it to penetrate the market quickly and efficiently.”

Due to the high interest, the initially planned size of 1.8 MCHF has been oversubscribed. Furthermore, the Lumendo management and board will accept additional funds until Q1 2022. In case of interest, contact us directly.

**About Lumendo:** Incorporated in Switzerland in 2018 as Spin-off of the two Swiss Federal Institutes of Technology – École Polytechnique Fédéral de Lausanne (EPFL) and Eidgenössische Technische Hochschule Zürich (ETH) – Lumendo is a well-recognized upcoming disruptor in the field of endodontics. Focusing on product excellence and a strong innovation stream, the goal of Lumendo is to develop easy-to-apply, reliable, and novel products to treat unsolved medical challenges.

**About the technology:** Root canal treatments are one of the most difficult treatments for dentists, traditionally with very low success rates between 46-91%<sup>1</sup>. With more than 60 million annual treatments worldwide, these failures lead to a substantial increase in health care costs.

One major cause of the treatment failure can be traced back to the use of endodontic files that may result in root or instrument fractures. Another issue is the inefficient identification and disinfection of the often very complex root canal anatomy. Finally, a major problem is the obturation of these geometrically complex morphologies with viscous or rubber-like materials that are difficult to be distributed adequately in narrow canals, leading to voids that can be reinfected.

The goal of Lumendo’s technology platform is to offer better treatment options to dentists and their patients. The company’s first products are planned to be launched in 2024.

Disclaimer: Lumendo’s devices are in development and not approved for clinical use under any jurisdiction.

---

<sup>1</sup> S. Friedman, “Prognosis of initial endodontic therapy,” *Endod. Top.*, vol. 2, no. 1, pp. 59–88, Jul. 2002.



For further information contact:

Lumendo AG

Chemin du Closel 5

CH-1020 Renens

Switzerland

[info@lumendo.ch](mailto:info@lumendo.ch)

[www.lumendo.ch](http://www.lumendo.ch)

